• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐药结核病 - 原发传播与管理。

Drug-Resistant tuberculosis - primary transmission and management.

机构信息

The Children's Hospital at Westmead and the Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.

The Children's Hospital at Westmead and the Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.

出版信息

J Infect. 2017 Jun;74 Suppl 1:S128-S135. doi: 10.1016/S0163-4453(17)30203-7.

DOI:10.1016/S0163-4453(17)30203-7
PMID:28646952
Abstract

The DOTS strategy assisted global tuberculosis (TB) control, but was unable to prevent the emergence and spread of drug-resistant strains. Genomic evidence confirms the transmission of drug-resistant Mycobacterium tuberculosis strains in many different settings, indicative of epidemic spread. These findings emphasise the need for enhanced infection control measures in health care and congregate settings. Young children in TB endemic areas are particularly vulnerable. Although advances in TB drug and vaccine development are urgently needed, improved access to currently available preventive therapy and treatment for drug resistant TB could reduce the disease burden and adverse outcomes experienced by children. We review new insights into the transmission dynamics of drug resistant TB, the estimated disease burden in children and optimal management strategies to consider.

摘要

DOTS 策略协助了全球结核病 (TB) 控制,但未能阻止耐药菌株的出现和传播。基因组证据证实了耐药结核分枝杆菌菌株在许多不同环境中的传播,表明存在流行传播。这些发现强调了需要在医疗保健和聚集场所加强感染控制措施。结核病流行地区的幼儿尤其脆弱。尽管迫切需要在结核病药物和疫苗开发方面取得进展,但增加获得现有耐药结核病预防性治疗和治疗的机会,可以减轻儿童的疾病负担和不良后果。我们回顾了耐药结核病传播动态、儿童疾病负担和最佳管理策略方面的新见解。

相似文献

1
Drug-Resistant tuberculosis - primary transmission and management.耐药结核病 - 原发传播与管理。
J Infect. 2017 Jun;74 Suppl 1:S128-S135. doi: 10.1016/S0163-4453(17)30203-7.
2
Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases.预防耐多药结核病的传播和保护传染病接触者。
Clin Microbiol Infect. 2017 Mar;23(3):147-153. doi: 10.1016/j.cmi.2016.08.024. Epub 2016 Aug 31.
3
The global tuberculosis situation and the inexorable rise of drug-resistant disease.全球结核病状况和耐药疾病的不可阻挡上升。
Adv Drug Deliv Rev. 2016 Jul 1;102:3-9. doi: 10.1016/j.addr.2016.01.021. Epub 2016 Feb 12.
4
Strategies for halting the rise of multidrug resistant TB epidemics: assessing the effect of early case detection and isolation.遏制耐多药结核病疫情上升的策略:评估早期病例发现和隔离的效果。
Int Health. 2017 Mar 1;9(2):80-90. doi: 10.1093/inthealth/ihw059.
5
Issues facing TB control (7). Multiple drug-resistant tuberculosis.结核病控制面临的问题(7)。多重耐药结核病。
Scott Med J. 2000 Oct;45(5 Suppl):52-5; discussion 56. doi: 10.1177/00369330000450S124.
6
Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.耐多药和广泛耐药结核病成人和儿童的临床管理。
Clin Microbiol Infect. 2017 Mar;23(3):131-140. doi: 10.1016/j.cmi.2016.10.008. Epub 2016 Oct 15.
7
Multidrug-resistant and extensively drug-resistant tuberculosis: a review.耐多药和广泛耐药结核病:综述
Curr Opin Infect Dis. 2008 Dec;21(6):587-95. doi: 10.1097/QCO.0b013e328319bce6.
8
Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings.关闭水龙头:在资源有限的环境中减少耐药结核病传播。
Int J Tuberc Lung Dis. 2010 Oct;14(10):1233-43.
9
Cost-effectiveness of treating multidrug-resistant tuberculosis.治疗耐多药结核病的成本效益
PLoS Med. 2006 Jul;3(7):e241. doi: 10.1371/journal.pmed.0030241.
10
Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.台湾实施直接观察治疗短程化疗(DOTS)和 DOTS-Plus 方案后,获得性耐多药结核病发病率下降。
J Antimicrob Chemother. 2013 Aug;68(8):1910-6. doi: 10.1093/jac/dkt103. Epub 2013 Apr 10.

引用本文的文献

1
Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.中国湖南省耐多药结核病患者诊断和治疗延误的危险因素。
BMC Infect Dis. 2024 Feb 2;24(1):159. doi: 10.1186/s12879-024-09036-2.
2
Lymphocyte-Related Immunological Indicators for Stratifying Infection.淋巴细胞相关免疫指标在分层感染中的应用。
Front Immunol. 2021 Jun 30;12:658843. doi: 10.3389/fimmu.2021.658843. eCollection 2021.
3
The fourth national anti-tuberculosis drug resistance survey in Peru.秘鲁第四次全国抗结核药物耐药性调查。
Int J Tuberc Lung Dis. 2020 Feb 1;24(2):207-213. doi: 10.5588/ijtld.19.0186.
4
Transmission of drug-resistant tuberculosis in HIV-endemic settings.HIV 流行地区耐多药结核病的传播。
Lancet Infect Dis. 2019 Mar;19(3):e77-e88. doi: 10.1016/S1473-3099(18)30537-1. Epub 2018 Dec 13.
5
The never-ending story of the fight against tuberculosis: from Koch's bacillus to global control programs.抗击结核病的永不停歇的故事:从科赫氏杆菌到全球防治计划。
J Prev Med Hyg. 2018 Sep 28;59(3):E241-E247. doi: 10.15167/2421-4248/jpmh2018.59.3.1051. eCollection 2018 Sep.